|
Published by: Decision Resources
Published: Mar. 10, 2008 - 26 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Biology of Transplant Rejection
- Immune Response in Tissue Rejection
- T-Cell Activation
- B-Cell Activation
- Natural Killer Cell Response
- Types of Rejection
- Importance of HLA Matching in Preventing Organ Rejection
- Post-Transplant Survival Rates
- Prevalence of Organ Transplantation
- Current Therapies
- Treatment After Organ Transplantation
- Overview of Commonly Used Agents for Maintenance Therapy
- Azathioprine
- Corticosteroids
- Cyclosporine
- Mycophenolate
- Sirolimus
- Tacrolimus
- 2007 Market for Anti-Rejection Therapies
- Emerging Therapies and Their Commercial Potential
- Long-Acting Tacrolimus
- CP-690550
- Belatacept
- Outlook: Drivers, Constraints, and Development Strategies
- Tables
- 1. Immune System Mediators and Their Functions
- 2. U.S. Sales of Leading Branded Agents (Organ Transplant Market Only) to Prevent Organ Rejection, 2007
- 3. Agents in U.S. Development for the Prevention of Chronic Rejection, 2007
- Figures
- 1. Number of U.S. Organ Transplantations, 1988-2017
- 2. Number of U.S. Organ Transplants, by Organ, 2007
- 3. Mechanism of Action of Current Anti-Rejection Agents
- 4. U.S. Market Growth of Anti-Rejection Agents, 2000-2007
- 5. U.S. Market Share of Leading Anti-Rejection Agents, 2007
- 6. U.S. Prescribing Share of Leading Anti-Rejection Agents, 2007
AbstractIntroduction
The organ transplant market, though growing only slowly in recent years, offers substantial opportunities for
drug developers. This market encompasses therapies that must be taken lifelong, ensuring a steady stream
of revenue throughout a drug’s life cycle. Another attractive feature of this market is that it can serve as a
gateway to other, potentially more lucrative markets.
Get the Answers You Need to Shape Your Strategy
- Although the organ transplant market has seen slow growth, certain segments of the market offer greater opportunities.
What factors are constraining this market?
Will growth accelerate in coming years?
Which markets offer the greatest potential rewards?
- Current anti-rejection therapies provide satisfactory efficacy, but their side-effect profi les are a safety concern.
Which current therapies are associated with the most serious effects?
What are the greatest unmet needs in this market?
How can companies capitalize on these needs as they develop new therapies?
- Two leading agents in this market, Astellas’s Prograf and Roche/Chugai’s Cellcept, will soon go off-patent.
What will the advent of increased generic competition mean for the market?
Which agents will become the new market leaders?
Scope
- Biology of transplant rejection: immune response in tissue rejection, natural killer cell response, types of rejection, post-transplant survival rates.
- Prevalence of organ transplantation: number of transplants performed per year (including projections through 2017), number of transplants per organ, number of transplants by age-group.
- Current therapies: treatment after transplantation, commonly used maintenance therapies.
- Market for anti-rejection therapies:emerging therapies, long-acting tacrolimus, CP-690550, belatacept.
- Market outlook: drivers, constraints, development strategies.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2009
|
